Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a transformative class of medications in the management of type 2 diabetes, demonstrating an approximate 14 percent reduction in major adverse cardiovascular events. Initially developed
Tag: Glucagon-like peptide-1 receptor agonists
